Most patients report relief from intractable spasms
Chemodenervation therapy using botulinum toxin offers a low-risk option for often painful and disabling movement disorders that are difficult to treat. Success rates for improving symptoms merit trying this treatment before embarking on a surgical course of action.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Outcomes data from the use of this strategy in Cleveland Clinic’s Center for Neurological Restoration in 2015 reveal that a variety of difficult-to-treat movement disorders are amenable to improvement. Injected directly into involved muscles, botulinum toxin (Botox®, Dysport®, Myobloc® and Xeomin®) tends to be most effective in treating spastic disorders involving only a few muscle groups. Most patients require repeat injections every three to four months as the effects of the toxin wears off.
Of the 126 patients treated with botulinum toxin in 2015 at Cleveland Clinic for cervical dystonia (spasmodic torticollis) — most of whom had complex presentations — 62 percent rated their condition as improved on the Patient Global Impression of Improvement (PGI-I) questionnaire (see table below). This response rate was achieved despite the high acuity of patients and the fact that a significant portion of cases had failed to respond to botulinum toxin injections from other providers. Fewer than 20 percent of patients rated their condition as worse following treatment, with most rating it as minimally worse.
Other movement disorders, including other forms of dystonia, hemifacial spasm and spasticity, can also be treated with botulinum toxin, as can intractable migraine.
Out of all patients treated with chemodenervation at Cleveland Clinic in 2015 (N = 237), including those with medication-resistant migraine, hemifacial spasms and dystonia, more than half (53 percent) rated their condition as improved on the PGI-I questionnaire (see table below). Of the approximately 20 percent who reported their condition as worse, most rated the worsening as minimal.
Cleveland Clinic systematically collects and reports quality and outcomes measures for other treatments for movement disorders, including spinal cord stimulation and deep brain stimulation. These data, as well as outcomes for the full range of neurological disorders treated at Cleveland Clinic, can be accessed online in the 2015 Neurological Institute Outcomes Book.
Favorable rates may stem from focus on outcomes monitoring
Nearly two-thirds of patients see clinically meaningful gains in large series
Treatment outcomes validate clinic's group-therapy approach
Insights from the first studies of HCAHPS data in this setting
Collaboration, institutionalizing best practices are central
Outcomes outtakes ranging from home sleep testing to QoL effects
Diversifying the mix with intensive outpatient care, shared appointments
Empowering athletic trainers to better assess, report and monitor head injury